Oral GLP-1 Candidate Aleniglipron Posts Weight Loss Data Rivaling Wegovy Pill in Phase II Trial
Structure Therapeutics recently shared new results from its latest obesity study. The data shows that their oral drug, aleniglipron, helps people lose weight effectively. These results look very similar to the weight loss seen with the current Wegovy pill. In view of this, this new drug could become a strong competitor in the market.
People taking a high dose of aleniglipron lost about 16.3 percent of their body weight. This happened over a period of 44 weeks during the clinical trial. Meanwhile, the Wegovy pill showed 13.9 percent weight loss in a longer study. Therefore, aleniglipron ranks among the most powerful oral options currently being tested by scientists.
Researchers noticed that patients did not stop losing weight during the trial. Usually, weight loss slows down or hits a wall after several months. This did not happen here, suggesting that longer treatment might lead to even more progress. Building on this, the full potential of the drug remains unknown for now.
The study also showed that most patients handled the medication quite well. Less than 4 percent of people had to stop taking the drug due to side effects. This is a lower rate than what researchers saw in similar studies for Wegovy. Consequently, aleniglipron might be easier for the average person to take every day.
This new drug is a small molecule pill, which is different from older injectable medicines. It does not need special coatings to help the body absorb it properly. This makes the pill simpler to produce and potentially easier for patients to use. Moreover, this unique structure could allow for more flexible dosing schedules in the future.
Market experts reviewed these findings and feel cautious about the current leading brands. Many companies are now developing their own weight loss pills at the same time. This creates a lot of competition for the businesses that currently dominate the market. Thus, the long-term leader in obesity treatment is still very much up in the air.
Aleniglipron still needs to go through one more major round of testing. This phase III testing is required before federal agencies can approve it for public use. Regulators want to see that the drug is safe for the heart over a long time. Accordingly, the company plans to start these large-scale studies by the end of 2026.
Right now, most people use shots to take these types of weight loss drugs. However, many patients and doctors would prefer a simple pill they can swallow. Transitioning to pills could make these important treatments available to many more people. Given this, the success of the next trial will decide if this drug becomes a reality.
The pharmaceutical industry is watching these developments with great interest. The shift from weekly injections to daily pills represents a massive change in patient care. Along with this, manufacturing a small-molecule pill is often cheaper than creating complex proteins. Therefore, insurance companies might favor these newer oral options to save on costs.
Developing a new drug is a very long and expensive process for any company. Every successful trial brings a team closer to helping millions of people manage their health. Nevertheless, the road to a final pharmacy shelf remains filled with strict regulatory hurdles. As a result, only the most consistent and safe medications actually reach the public.
